SLU-PP-332 Overview, Dosing & Safety | Peptide Database

SLU-PP-332 (Exercise Mimetic)

Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator

Community Research

Join others researching SLU-PP-332 — share findings, ask questions, and learn from real experiences

Groundbreaking synthetic compound from Saint Louis University functioning as pan-estrogen-related receptor agonist with preferential ERRα activity. Activates metabolic pathways engaged during physical exercise without physical activity requirement.

Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.8-fold, enhances oxidative phosphorylation and ATP production.

Molecular Data

Complex or non-standard sequence format

Research Indications

12% body weight reduction in 28 days without appetite suppression. Fat mass gain <0.5g vs ~5g controls.

Significantly improved glucose tolerance in obese mice with lower fasting glucose and insulin levels.

Increases resting energy expenditure by 25% for fatty acid oxidation within 2 hours.

Reduced hepatic steatosis, decreased hepatic triglycerides, and enhanced hepatic fatty acid oxidation.

70% increase in running time and 45% increase in running distance in preclinical models.

Increased type IIa oxidative skeletal muscle fibers with enhanced oxidative capacity.

Improved ejection fraction in heart failure models with reduced cardiac fibrosis.

First compound to reverse age-related mitochondrial dysfunction in 21-month-old mice.

Reversed age-related albuminuria increase and prevented podocyte loss in elderly mice.

Dosing Protocols

Research compound - IP injection in animals only. No human administration protocols established.

Standard Metabolic Protocol

50 mg/kg (animal dosing)

Twice daily

Intraperitoneal injection (IP)

Acute Exercise Enhancement

Single dose 1 hour pre-exercise

Extended Treatment

Twice daily for 4-8 weeks

Reconstitution Instructions

Bacteriostatic water (BAC) required

Sterile technique essential

1 WARNING: Not tested in humans - research only

2 Do NOT use outside approved research protocols

3 Dosing cannot be extrapolated from animals to humans

4 No human clinical trials initiated as of 2025

5 Oral formulation in development

6 Consult medical professionals before experimental use

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Animal studies show favorable safety with no severe effects at therapeutic doses

Well-tolerated in rodents and canines

No liver, kidney, or cardiac toxicity documented

No lean mass loss

Does not suppress hormones or act as stimulant

Minor plasma cholesterol and liver enzyme changes in some studies

Stop Signs - Discontinue if:

Severe hypoglycemia (especially with diabetes medications)

Any cardiovascular symptoms (chest pain, palpitations, shortness of breath)

Signs of liver dysfunction (jaundice, dark urine, severe abdominal pain)

Kidney problems (reduced urination, swelling, severe back pain)

Severe headaches or neurological symptoms

Allergic reactions (rash, hives, difficulty breathing, swelling)

Contraindications

NOT FOR HUMAN USE - no approved human dose

No human clinical trials conducted

Potential interaction with diabetes medications

Quality Checklist

Good Signs

Legitimate research supplier with Certificate of Analysis

From reputable chemical suppliers (Cayman Chemical, Sigma-Aldrich)

Proper labeling as 'Research Use Only'

Batch numbers and purity data (typically >98%)

Warning Signs

Research chemical only - NOT FOR HUMAN USE

NOT FDA approved - no human clinical trials

Available only for legitimate research through licensed suppliers

Bad Signs

Any product marketed for human consumption is illegal

Unknown purity or contamination without lab testing

Lack of proper HPLC or mass spectrometry verification

Products without 'Research Use Only' labeling

Frequently Asked Questions

Is SLU-PP-332 an actual exercise substitute, or does it just feel like you worked out?

SLU-PP-332 activates the same metabolic pathways exercise does (mitochondrial biogenesis, PGC-1α upregulation, AMPK activation), but it's not a complete substitute. It increases endurance 70% and reduces weight 12% without exercise, but it doesn't build muscles or improve cardiovascular fitness like real training does. Think of it as metabolic enhancement, not exercise replacement.

Why does SLU-PP-332 work so much faster than training (12% weight loss in 28 days)?

Training requires weeks to upregulate mitochondrial genes; SLU-PP-332 activates them within hours. In mouse studies, energy expenditure increased 25% within 2 hours, creating sustained fat oxidation and rapid weight loss. This bypass of normal training adaptation pathways explains the speed, though long-term human data doesn't exist.

Could SLU-PP-332 cause liver damage if used long-term?

The file flags SLU-PP-332 as potentially hepatotoxic. However, animal studies showed no liver damage at therapeutic doses. The flag exists because long-term human safety is unknown. If used experimentally, liver function tests (ALT, AST, bilirubin) should be monitored regularly.

Is there an oral version of SLU-PP-332 in development?

Yes. SLU-PP-915 (a distinct oral bioavailable ERR pan-agonist) shows similar efficacy to SLU-PP-332 when given orally. A 2025 study found it enhanced aerobic performance as effectively as the injectable form. This represents major progress toward clinical translation, though human trials haven't started.

References

Diet-induced obese mice, 50 mg/kg IP twice daily, 28 days: 12% body weight loss, 25% fatty acid oxidation increase, improved glucose tolerance, reduced hepatic steatosis. SLU-PP-332 mimics exercise-induced metabolic benefits.

Multiple mouse models, 50 mg/kg IP: 70% increase in running time, 45% increase in running distance, increased type IIa oxidative muscle fibers. SLU-PP-332 is a synthetic ERR pan agonist with highest potency for ERRα.

21-month-old mice, 8-week treatment with SLU-PP-332: Reversed age-related increases in albuminuria, podocyte loss, mitochondrial dysfunction, and inflammatory cytokines.

Both SLU-PP-332 and SLU-PP-915 significantly improved ejection fraction, ameliorated fibrosis, and increased survival in pressure overload-induced heart failure without affecting cardiac hypertrophy. Transcriptionally activated fatty acid metabolism and mitochondrial function genes.

Related Peptides

Distinct mechanisms (ERR agonism vs NNMT inhibition) likely complementary without known interactions.

Complementary mitochondrial pathways - SLU-PP-332 increases biogenesis while NAD+ supports energy production.

May preserve lean muscle during SLU-PP-332-induced fat loss through GH pathway.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.